XZP-5809 / Sihuan Pharmaceutical - LARVOL DELTA

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=21 | Terminated | Sponsor: Sihuan Pharmaceutical Holdings Group Ltd. | N=90 ➔ 21 | Trial completion date: Sep 2022 ➔ Apr 2022 | Recruiting ➔ Terminated; Strategic considerations

Enrollment change • Metastases • Trial completion date • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR